In Vázquez-Medina et al.’s study, they found that ARB treatment could improve damaged insulin signaling and maintain cellular energy balance during metabolic syndrome by increasing AMPK activity in the heart [114–116]. The gene discussed is PRKAA2; the disease is metabolic syndrome.